Inhibit versus Destroy: Are PROTAC Degraders the Solution to Targeting STAT3?

Publication date: 11 November 2019Source: Cancer Cell, Volume 36, Issue 5Author(s): Lisa N. Heppler, David A. FrankDespite the role of STAT3 as a known driver of oncogenesis, efforts to develop therapeutic STAT3 inhibitors have thus far been unsuccessful. In this issue of Cancer Cell, Bai et al. report a potent and selective STAT3 degrader capable of producing complete and long-lasting tumor regression in mouse xenograft models.
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research